Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate triple therapy versus dual therapies in patients with COPD and additional asthma features: Post-hoc analysis of KRONOS and ETHOS

被引：0
|
作者：
Seki, Munehiro [1 ]
Muro, Shigeo [2 ]
Hurst, John R. [3 ]
Petullo, David [4 ]
Darken, Patrick [4 ]
Megally, Ayman [5 ]
Patel, Mehul [6 ]
机构：
[1] AstraZeneca KK, Dept Med, Resp Inhalat, Osaka, Japan
[2] Nara Med Univ, Dept Resp Med, Nara, Japan
[3] UCL, UCL Resp, London, England
[4] AstraZeneca, Late RIA Biometr, Gaithersburg, MD USA
[5] AstraZeneca, Late RIA, Biopharmaceut R&D, Gaithersburg, MD USA
[6] AstraZeneca, Late RIA, Biopharmaceut R&D, Cambridge, England
来源：
RESPIROLOGY | 2023年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AO23-1
引用
收藏
页码：126 / 127
页数：2
相关论文
共 50 条
  • [1] Triple Therapy with Budesonide/Glycopyrronium/ Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS
    Muro, Shigeo
    Seki, Munehiro
    Hurst, John R.
    Petullo, David
    Marshall, Jonathan
    Bowen, Karin
    Darken, Patrick F.
    Duncan, Elizabeth A.
    Megally, Ayman
    Patel, Mehul
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2024, 19 : 2729 - 2737
  • [2] Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history
    Muro, Shigeo
    Kawayama, Tomotaka
    Sugiura, Hisatoshi
    Seki, Munehiro
    Duncan, Elizabeth A.
    Bowen, Karin
    Marshall, Jonathan
    Megally, Ayman
    Patel, Mehul
    RESPIRATORY RESEARCH, 2024, 25 (01)
  • [3] Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS
    Bafadhel, Mona
    Rabe, Klaus F.
    Martinez, Fernando J.
    Singh, Dave
    Darken, Patrick
    Jenkins, Martin
    Aurivillius, Magnus
    Patel, Mehul
    Dorinsky, Paul
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 3061 - 3073
  • [4] RATE OF SEVERE COPD EXACERBATIONS WITH BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL FUMA-RATE DIHYDRATE METERED DOSE INHALER (BGF MDI) VERSUS DUAL THERAPIES: A POST-HOC SUBGROUP ANALYSIS OF THE ETHOS TRIAL
    Ferguson, G. T.
    Rabe, K. F.
    Martinez, F. J.
    Singh, D.
    Trivedi, R.
    Darken, P.
    Jenkins, M.
    Aurivillius, M.
    Dorinsky, P.
    THORAX, 2021, 76 : A16 - A16
  • [5] COST-EFFECTIVENESS OF TRIPLE THERAPY WITH BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL FUMARATE VERSUS DUAL THERAPIES IN MODERATE-TO-VERY SEVERE COPD IN THE UNITED KINGDOM: ANALYSIS BASED ON THE KRONOS STUDY
    de Nigris, E.
    Holmgren, U.
    Treharne, C.
    Brighton, N.
    Walker, A.
    Haughney, J.
    THORAX, 2021, 76 : A66 - A66
  • [6] A Post-Hoc Analysis of the Effect of Smoking Status on COPD Exacerbation Reductions with Budesonide/Glycopyrrolate/Formoterol Fumarate in Patients with COPD in the ETHOS Study
    Bafadhel, M.
    Han, M. K.
    Singh, D.
    Jenkins, M.
    Dorinsky, P.
    Patel, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [7] COST-EFFECTIVENESS OF TRIPLE THERAPY WITH BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL FUMARATE VERSUS DUAL THERAPIES IN MODERATE-TO-VERY SEVERE COPD: UNITED KINGDOM ANALYSIS USING THE ETHOS STUDY
    de Nigris, E.
    Treharne, C.
    Brighton, N.
    Holmgren, U.
    Jenkins, M.
    Walker, A.
    Haughney, J.
    VALUE IN HEALTH, 2022, 25 (01) : S46 - S46
  • [8] Effect of Triple Inhaled Therapy With Budesonide/Glycopyrrolate/Formoterol Fumarate on Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post-hoc Analysis of ETHOS
    Singh, D.
    Martinez, F. J.
    Hurst, J. R.
    Han, M. K.
    Gale, C. P.
    Fredriksson, M.
    Kisielewicz, D.
    Mushunje, A.
    Movitz, C.
    Ojili, N.
    Parikh, H.
    Arya, N.
    Bowen, K.
    Patel, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [9] Rate of Severe COPD Exacerbations with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Dual Therapies: A Post-Hoc Analysis of the ETHOS Trial Excluding Data from China
    Ferguson, G. T.
    Rabe, K. F.
    Martinez, F. J.
    Wang, C.
    Trivedi, R.
    St Rose, E.
    Ballal, S.
    McLaren, J.
    Darken, P.
    Aurivillius, M.
    Dorinsky, P.
    Reisner, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [10] Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study
    De Nigris, Enrico
    Treharne, Catrin
    Brighton, Nick
    Holmgren, Ulf
    Walker, Andrew
    Haughney, John
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 2987 - 3000
12345